Serina Historical Financial Ratios
| SER Stock | 4.79 0.64 15.42% |
Serina Therapeutics is promptly reporting on over 75 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as Book Value Per Share of 5.21, Invested Capital of 0.0, Average Payables of 817.1 K or Stock Based Compensation To Revenue of 0.0229 will help investors to properly organize and evaluate Serina Therapeutics financial condition quickly.
Serina |
About Serina Financial Ratios Analysis
Serina TherapeuticsFinancial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Serina Therapeutics investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Serina financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Serina Therapeutics history.
Serina Therapeutics Financial Ratios Chart
Add Fundamental
Price To Sales Ratio
Price to Sales Ratio is figured by comparing Serina Therapeutics stock price to its revenues. An advantage to using Price to Sales ratio is that it is based on Serina Therapeutics sales, a figure that is much harder to manipulate than other Serina Therapeutics multiples. Because sales tend to be more stable P/S ratio can be a good tool for screening cyclical companies fluctuating earnings patterns. A valuation ratio that compares a company's stock price to its revenues, calculated by dividing the company's market cap by its total sales or revenue over a 12-month period.Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Stock Based Compensation To Revenue
A metric that compares the total value of stock-based compensation granted by a company to its total revenue, indicating how much of the revenue is used to compensate employees with stock options or awards.Research And Ddevelopement To Revenue
The ratio of a company's research and development expenses to its total revenue, indicating how much of the revenue is invested back into developing new products or services.Most ratios from Serina Therapeutics' fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Serina Therapeutics current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Serina Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in income. To learn how to invest in Serina Stock, please use our How to Invest in Serina Therapeutics guide.At this time, Serina Therapeutics' Shareholders Equity Per Share is relatively stable compared to the past year. As of 12/18/2024, Debt To Equity is likely to grow to 0.84, while Days Sales Outstanding is likely to drop 125.27.
| 2021 | 2022 | 2023 | 2024 (projected) | Graham Number | 29.34 | 44.26 | 39.55 | 44.83 | Receivables Turnover | 2.7K | 2.49 | 2.24 | 2.13 |
Serina Therapeutics fundamentals Correlations
Click cells to compare fundamentals
Serina Therapeutics Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Serina Therapeutics fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Price To Sales Ratio | 39.86 | 1.1K | 13.8 | 42.53 | 104.48 | 148.28 | |
| Ptb Ratio | 31.06 | (11.37) | (1.19) | (0.56) | 2.71 | 2.58 | |
| Days Sales Outstanding | 76.68 | 2.2K | 0.13 | 146.51 | 131.86 | 125.27 | |
| Book Value Per Share | 2.47 | (5.04) | (32.59) | (35.02) | 4.97 | 5.21 | |
| Free Cash Flow Yield | (0.16) | (0.13) | (0.0563) | (0.0981) | (0.53) | (0.5) | |
| Operating Cash Flow Per Share | (9.59) | (7.3) | (2.09) | (1.92) | (7.23) | (7.59) | |
| Capex To Depreciation | 3.54 | 0.67 | 0.0159 | 3.25 | 0.16 | 0.14 | |
| Pb Ratio | 31.06 | (11.37) | (1.19) | (0.56) | 2.71 | 2.58 | |
| Ev To Sales | 39.63 | 1.2K | 13.83 | 45.08 | 132.79 | 161.02 | |
| Free Cash Flow Per Share | (10.19) | (7.32) | (2.19) | (1.93) | (7.23) | (7.59) | |
| Roic | (3.05) | (9.21) | 0.0466 | 0.0569 | (1.01) | (1.06) | |
| Net Income Per Share | (11.47) | (10.14) | (1.17) | (2.49) | (13.72) | (13.03) | |
| Payables Turnover | 2.38 | 1.68 | 1.03 | 1.01 | 0.12 | 0.11 | |
| Research And Ddevelopement To Revenue | 3.09 | 66.33 | 1.25 | 3.15 | 4.25 | 4.03 | |
| Cash Per Share | 6.76 | 2.22 | 0.49 | 1.22 | 0.32 | 0.3 | |
| Pocfratio | (6.78) | (7.44) | (18.63) | (10.25) | (1.9) | (2.0) | |
| Capex To Operating Cash Flow | (0.0631) | (0.002559) | (0.0482) | (0.004665) | (0.004198) | (0.004408) | |
| Pfcf Ratio | (6.38) | (7.42) | (17.78) | (10.2) | (1.9) | (2.0) | |
| Days Payables Outstanding | 153.53 | 216.83 | 353.97 | 360.81 | 3.0K | 3.2K | |
| Income Quality | 0.84 | 0.75 | 1.78 | 0.77 | 0.53 | 0.72 | |
| Roe | (5.48) | 2.12 | 0.036 | 0.071 | (2.71) | (2.57) | |
| Ev To Operating Cash Flow | (6.74) | (8.18) | (18.67) | (10.86) | (2.42) | (2.54) | |
| Pe Ratio | (5.67) | (5.35) | (33.16) | (7.93) | (1.0) | (1.05) | |
| Return On Tangible Assets | (1.63) | (2.77) | (0.69) | (3.13) | (1.3) | (1.37) | |
| Ev To Free Cash Flow | (6.34) | (8.16) | (17.81) | (10.81) | (2.42) | (2.54) | |
| Earnings Yield | (0.18) | (0.19) | (0.0302) | (0.13) | (1.0) | (0.95) | |
| Net Debt To E B I T D A | 0.0341 | (0.66) | (0.0525) | (0.49) | (0.41) | (0.39) | |
| Current Ratio | 1.23 | 0.43 | 3.58 | 1.25 | 0.13 | 0.12 | |
| Tangible Book Value Per Share | 2.47 | (5.04) | (32.59) | (35.02) | 4.4 | 4.62 | |
| Receivables Turnover | 4.76 | 0.17 | 2.7K | 2.49 | 2.24 | 2.13 | |
| Graham Number | 23.24 | 33.02 | 29.34 | 44.26 | 39.55 | 44.83 | |
| Shareholders Equity Per Share | 2.09 | (4.78) | (32.59) | (35.02) | 5.07 | 5.32 | |
| Capex Per Share | 0.6 | 0.0187 | 0.1 | 0.008974 | 0.0103 | 0.009804 | |
| Graham Net Net | (2.08) | (7.98) | (33.83) | (36.15) | (5.76) | (6.05) | |
| Revenue Per Share | 1.41 | 1.63 | 0.0504 | 2.82 | 0.46 | 0.13 |
Pair Trading with Serina Therapeutics
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Serina Therapeutics position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Serina Therapeutics will appreciate offsetting losses from the drop in the long position's value.Moving together with Serina Stock
Moving against Serina Stock
| 0.73 | GILD | Gilead Sciences | PairCorr |
| 0.71 | BMY | Bristol Myers Squibb | PairCorr |
| 0.62 | DYAI | Dyadic International | PairCorr |
| 0.53 | ESPR | Esperion Therapeutics Buyout Trend | PairCorr |
The ability to find closely correlated positions to Serina Therapeutics could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Serina Therapeutics when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Serina Therapeutics - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Serina Therapeutics to buy it.
The correlation of Serina Therapeutics is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Serina Therapeutics moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Serina Therapeutics moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Serina Therapeutics can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Serina Stock Analysis
When running Serina Therapeutics' price analysis, check to measure Serina Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Serina Therapeutics is operating at the current time. Most of Serina Therapeutics' value examination focuses on studying past and present price action to predict the probability of Serina Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Serina Therapeutics' price. Additionally, you may evaluate how the addition of Serina Therapeutics to your portfolios can decrease your overall portfolio volatility.